Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco, East Bay
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Please contact: ClinicalResearch@sutterhealth.org about study Librexia
Location: CPMC (San Francisco)
Location: REDI (East Bay) Contact: Lilly Murray, RN
Principal Investigator
Peter Adamczyk, M.D, Brian C. Richardson, M.D., Nobl Barazangi, M.D., Ph.D.